021 Effects of Low-dose Triple Combination Therapy on Therapeutic Inertia and Prescribing Patterns in Hypertension – Results from the TRIUMPH Trial

Wang, N.; Salam, Abdul; Silva, A. De; Guggilla, Rama; Stepien, Sandrine; Mysore, Jayanthi; Billot, Laurent; Jan, S.; Maulik, Pallab K.; Naik, Niyaz A.; Selak, Vanessa; Thom, Simon; Prabhakaran, Dorairaj; Patel, Anushka; Rodgers, Anthony

doi:10.1016/j.hlc.2020.09.028

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…antihypertensive triple-drug FDC therapy (telmisartan 20 mg; amlodipine 2.5 mg; and chlorthalidone 12.5 mg) with therapeutic inertia and prescribing patterns vs. usual care. The result from the study suggests that triple FDC therapy was associated with greater rates of therapeutic inertia, substantially simplified prescribing patterns, and improved 6-month BP control rates compared with usual care [45]. A prospective, open-label study in India evaluated the efficacy of the combination of chlorthalidone and telmisartan in patients with hypertension who did not respond to hydrochlorothiazide and telmisartan combination.…”

Section: Table 2 Continuedmentioning

confidence: 99%

Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study

et al. 2021

View full text Add to dashboard Cite

Introduction:The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy.Methods: In this phase III, open-label, multicenter study, 254 adults with stable CAD having uncontrolled hypertension despite being treated with FDC of metoprolol (25/50 mg) and telmisartan (40 mg) were included. Patients received either of the following FDC for 24 weeks: metoprolol (25 mg), telmisartan (40 mg), and chlorthalidone (12.5 mg) (FDC1; n = 139) or metoprolol (50 mg), telmisartan (40 mg), and chlorthalidone (12.5 mg) (FDC2; n = 115) tablets once daily. The FDCs were developed using the novel Wrap Matrix TM

show abstract

Section: Table 2 Continuedmentioning

confidence: 99%